@article{d1f529e006114d2093b187dfe4eea0b0,
title = "Reply to: The Association Between Cognitive Decline and Bone Loss and Fracture Risk Is Not Affected by Medication With Anticholinergic Effect",
author = "Dana Bliuc and Thach Tran and Adachi, \{Jonathan D\} and Atkins, \{Gerald J\} and Claudie Berger and \{van den Bergh\}, Joop and Roberto Cappai and Eisman, \{John A\} and \{van Geel\}, Tineke and Piet Geusens and David Goltzman and Hanley, \{David A\} and Robert Josse and Stephanie Kaiser and Kovacs, \{Christopher S\} and Lisa Langsetmo and Prior, \{Jerilynn C\} and Nguyen, \{Tuan V\} and Solomon, \{Lucian B\} and Catherine Stapledon and Center, \{Jacqueline R\} and \{CaMos Research Group\}",
note = "Funding Information: DB, TT, TvG, CB, DG, RGJ, LL, GJA, LBS, RC, CJS, CSK, SMK and JCP have no competing interests to declare. JDA has received research grants and/or personal fees from Amgen, Eli Lilly, Merck, Actavis and AgNovos. JvdB has received grants and/or personal fees from Amgen, MSD, and Eli Lilly. JAE has consulted for and/or received research funding from Amgen, deCode, Merck Sharp and Dohme, and Sanofi‐Aventis. PG was advisory member for Amgen, has received speaker fee and/or research grants from Amgen, Pfizer, MSD, UCB, Abbott, Lilly, BMS, Novartis, Roche and Will Pharma. DAH has consulted for and/or received speaker fee and /or research funding from Amgen, Merck and Eli Lilly. TVN has received honoraria for consulting and symposia from Merck Sharp and Dohme, Roche, Servier, Sanofi‐Aventis, and Novartis. JRC has consulted for and/or given educational talks for Merck Sharp and Dohme, Amgen, Actavis, Bayer and Sanofi‐Aventis.",
year = "2022",
month = may,
doi = "10.1002/jbmr.4530",
language = "English",
volume = "37",
pages = "1075--1076",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Oxford University Press",
number = "5",
}